The GPNMB Knockout TE1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the human esophageal squamous cell carcinoma cell line TE1, designed to disrupt GPNMB expression. This loss-of-function model enables investigation of GPNMB-dependent processes in malignant esophageal epithelial cells. The polyclonal format preserves genetic diversity, allowing functional studies without clonal selection artifacts, and is suitable for assessing context-specific roles in adhesion, migration, invasion, and tumor-stroma interactions.
The TE1 cell line originates from a human esophageal squamous cell carcinoma and exhibits invasive characteristics typical of advanced disease. These cells serve as a canonical in vitro system for esophageal cancer research, faithfully recapitulating key features of tumor cell biology. The genetic background provides an ideal platform to evaluate the contribution of GPNMB to the malignant phenotype, including alterations in motility, proliferation, and therapeutic response.
GPNMB is a type I transmembrane glycoprotein that engages integrin receptors ??v??3 and ??5??1 and syndecan-4 to trigger intracellular signaling. Upon activation, it stimulates phosphorylation of FAK and Src, leading to downstream activation of ERK1/2 and AKT. These pathways drive expression of cyclin D1, c-Myc, and matrix metalloproteinases, thereby enhancing proliferation and invasion. GPNMB expression is regulated by MITF, TGF-??, and EGF, and it can intersect with TGF-??-Smad and PI3K-AKT-mTOR axes, positioning it as a central node in growth factor and adhesion signaling.
In esophageal squamous cell carcinoma, GPNMB overexpression correlates with aggressive behavior, making this knockout model valuable for mechanistic dissection. By comparing GPNMB-disrupted TE1 cells with parental controls, researchers can define its specific impact on ERK/MAPK and AKT/mTOR signaling, cytoskeletal reorganization, and cell-ECM adhesion. The model is well suited for probing GPNMB??s role in drug resistance and stromal communication, offering insights into its potential as a therapeutic target.
Applications include western blotting, RT-qPCR, RNA-seq, and functional assays such as Boyden chamber migration/invasion, proliferation, and phospho-protein analysis. Co-immunoprecipitation, immunofluorescence, and flow cytometry enable interaction and localization studies, while drug sensitivity tests assess therapeutic relevance. For technical inquiries, contact Ascent Research.
